Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial.
By D. Kimberlin, Chin-Yu Lin, P. Sánchez, G. Demmler, W. Dankner, M. Shelton, R. Jacobs, W. Vaudry, R. Pass, Jan Kiell and 2 more. Jornal de Pediatria, 2003
870 citations recorded by the source corpus.
Subfields: Epidemiology, Immunology, Ophthalmology
View Paper: https://www.semanticscholar.org/paper/d7cf713ad913cac2670386c2bba58ac49b348fb8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- The “Silent” Global Burden of Congenital Cytomegalovirus (2013, background): “At 12 months of follow-up, a considerably higher rate of preserved normal hearing, as well as improved hearing and prevention of worsening of hearing in those with a baseline hearing deficit, was demonstrated following a 6-week course of intravenous GCV, compared with no therapy (95).”
- Valganciclovir for Symptomatic Congenital Cytomegalovirus Disease (2015, neutral): “hearing outcomes between baseline and 6 months, but there was suggestion that this benefit wanes over the first 2 years of life.(13) Based on these data, change in best-ear hearing between baseline and 6 months was selected as the primary endpoint of this trial.”
- Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection (2007, background): “[7], and newborn screening for early diagnosis of delayed hearing loss [8] or treatment with antiviral therapy [9].”